Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies
Table 1
Stratified analysis of efficacy outcomes according to anticoagulant mechanism.
Number of reports
Pooled RR (95% CI)
value
(%)
Stroke
Overall estimation
4
0.56 (0.45-0.70)
<0.0001
78
Anti-IIa agents
1
0.64 (0.48-0.85)
0.002
Anti-Xa agents
3
0.54 (0.41-0.71)
<0.0001
85
Ischemic stroke
Overall estimation
6
0.61 (0.48-0.78)
<0.0001
79
Anti-IIa agents
1
0.80 (0.58-1.10)
0.17
Anti-Xa agents
5
0.58 (0.43-0.77)
<0.0001
82
Stroke/systemic embolism
Overall estimation
8
0.80 (0.68-0.95)
0.01
88
Anti-IIa agents
2
0.79 (0.55-1.13)
0.19
82
Anti-Xa agents
6
0.81 (0.65-1.00)
0.047
90
Myocardial infarction
Overall estimation
8
0.69 (0.55-0.88)
0.002
61
Anti-IIa agents
2
0.66 (0.35-1.25)
0.201
52
Anti-Xa agents
6
0.67 (0.50-0.91)
0.011
68
MACE
Overall estimation
5
0.87 (0.75-1.00)
0.049
82
Anti-IIa agents
1
0.91 (0.81-1.01)
0.084
Anti-Xa agents
4
0.85 (0.70-1.04)
0.112
87
Anti-IIa agents include dabigatran. Anti-Xa agents include apixaban, edoxaban, and rivaroxaban. CI: confdence interval; MACE: major adverse cardiac events; RR: relative risk.
